Active Ingredient History

  • Now
Cerlapirdine is a drug which was under development by Wyeth/Pfizer for the treatment of cognitive disorders associated with Alzheimer's disease and schizophrenia. In a phase II clinical trial it demonstrated a trend toward efficacy along with a good side effect profile and no incidence of serious adverse events, but no further development has occurred since 2011.   Wikipedia

  • SMILES: CN(C)CCCOc1ccc2[nH]nc(c2c1)S(=O)(=O)c3cccc4ccccc34
  • Mol. Mass: 409.51
  • ALogP: 3.88
  • ChEMBL Molecule:
More Chemistry
cerlapirdine | pf-05212365 | sam-531 | way-262531


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue